Peptide derived from stromal cell-derived factor 1δ enhances the expression of osteogenic proteins bone marrow stromal cell differentiation and promotes bone formation in models

• Published in: Biomaterials science Vol. 11; no. 19; pp. 6587 - 6599
• Main Authors: Seon, Jong Keun, Kuppa, Sree Samanvitha, Kang, Ju Yeon, Lee, Jun Sik, Park, Su A, Yoon, Taek Rim, Park, Kyung Soon, Kim, Hyung Keun
• Format: Journal Article
• Published: 26.09.2023
• ISSN: 2047-4830; 2047-4849
• DOI: 10.1039/d3bm00798g

Mesenchymal stem cells (MSCs) rely on chemokines and chemokine receptors to execute their biological and physiological functions. Stromal cell-derived factor-1 (SDF-1) is upregulated in injury sites, where it acts as a chemotactic agent, attracting CXCR4-expressing MSCs, which play a pivotal role in the healing and regeneration of tissue throughout the body. Furthermore, SDF-1 expression has been observed in regions experiencing inflammation-induced bone destruction and fracture sites. In this study, we identified a novel peptide called bone-forming peptide-5 (BFP-5), derived from SDF-1δ, which can promote the osteogenesis of MSCs as well as bone formation and healing. Multipotent bone marrow stromal cells treated with BFP-5 showed enhanced alizarin red S staining and higher alkaline phosphatase (ALP) activity. Moreover, ALP and osterix proteins were more abundantly expressed when cells were treated with BFP-5 than SDF-1α. Histology and microcomputed tomography data at 12 weeks demonstrated that both rabbit and goat models transplanted with polycaprolactone (PCL) scaffolds coated with BFP-5 showed significantly greater bone formation than animals transplanted with PCL scaffolds alone. These findings suggest that BFP-5 could be useful in the development of related therapies for conditions associated with bones. Utilizing BFP-5 peptide derived from SDF-1δ to attract CXCR4-expressing MSCs for enhanced bone regeneration and healing.